rituximab + bendamustine + cytarabine + dexamethasone

R-B(O)AD (more commonly referred to as the R-BAD regimen) is a salvage chemotherapy combination developed by Chonnam National University Hwasun Hospital for the treatment of relapsed or refractory primary central nervous system lymphoma (PCNSL). The regimen consists of the anti-CD20 monoclonal antibody rituximab, the alkylating agent bendamustine, the antimetabolite cytarabine (Ara-C), and the corticosteroid dexamethasone. It was evaluated in a Phase 2 pilot study (NCT03392714) which characterized the pharmacokinetics of bendamustine in the cerebrospinal fluid (CSF) and assessed the regimen's efficacy in patients who had failed prior methotrexate-based therapy. The study demonstrated an overall response rate (ORR) of 50%, although the treatment was associated with significant hematologic toxicities, including grade 3/4 neutropenia and thrombocytopenia. The name R-B(O)AD appears to be a variant notation of R-BAD, where the components are Rituximab, Bendamustine, Cytarabine (Ara-C), and Dexamethasone.

Other names

R-B(O)AD regimenR-BAD regimenRituximab-Bendamustine-Cytarabine-Dexamethasone